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Background: Previously undetected contributors to secondary osteoporosis and metabolic bone
diseases (SECOB) are frequently found inpatientswith osteoporosis, but theprevalence in patients
at the time they present with a clinical fracture is unknown.
Methods: All consecutive patients with a recent clinical vertebral or nonvertebral fracture, who
were able and willing to be investigated (n 626: 482 women, 144 men, age range 50–97 yr) had
bone mineral density and laboratory investigations (serum calcium, inorganic phosphate, 25-hy-
droxyvitamin D, creatinine, intact PTH, TSH, free T4, serum and urine protein electrophoresis, and
in men also serum testosterone).
Results:KnownSECOBcontributorswerepresent in23.0%ofpatients andnewlydiagnosedSECOB
contributors in 26.5%:monoclonal proteinemia (14 of 626), renal insufficiency grade III or greater
(54 of 626), primary (17 of 626) and secondary (64 of 626) hyperparathyroidism, hyperthyroidism
(39 of 626), and hypogonadism in men (12 of 144). Newly diagnosed SECOBs, serum 25-hydroxyvi-
taminD less than50nmol/liter (in63.9%), anddietary calcium intake less than1200mg/d (in90.6%)
were found at any age, in both sexes, after any fracture (except SECOB inmenwith finger and toe
fractures) and at any level of bone mineral density.
Conclusion: At presentation with a fracture, 26.5% of patients have previously unknown contrib-
utors to SECOB, which are treatable or need follow-up, and more than 90% of patients have an
inadequate vitamin D status and/or calcium intake. Systematic screening of patients with a recent
fracture identifies those in whom potentially reversible contributors to SECOB and calcium and
vitamin D deficiency are present. (J Clin Endocrinol Metab 96: 1360–1367, 2011)
Guidelines on osteoporosis advocate the evaluation ofpatients presenting with osteoporosis to exclude
diseases that mimic osteoporosis and identify the cause of
osteoporosis and contributory factors [National Osteo-
porosis Guideline Group (1, 2)] before therapy [National
Osteoporosis Foundation (3)] and in patients with or
without fracture [German guideline osteoporosis diagno-
sis and therapy (4)]. Many contributors to secondary os-
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teoporosis andmetabolicbonedisease (SECOB)havebeen
identified (3–5). If SECOB contributors are not recog-
nized, treatment to prevent fractures may be suboptimal
(6). Many contributors to SECOB are treatable [e.g. hy-
perthyroidism], need further investigation [e.g. idiopathic
hyperparathyroidism], or need follow-up [e.g. monoclo-
nal gammopathy of unknown significance (MGUS)].
In studies including various subgroups of patients with
osteoporosis and/or a recent fracture, SECOB was found
in 27–80%, including deficient calcium intake and vita-
min D deficiency (5, 7, 8).
Therefore, we evaluated the prevalence of contributors
to SECOB and low calcium intake and vitamin D defi-
ciency separately in consecutive patients at the time they
presented at the emergency unit of the hospital due to a
clinical vertebral or nonvertebral fracture.
Subjects and Methods
Study design and population
A prospectively planned cross-sectional chart review study
was conducted among men and women presenting with a newly
diagnosed clinical vertebral or nonvertebral fracture. Subjects
were all consecutive patients older than 50 yr who presented at
the emergency department of the VieCuri Hospital Noord-Lim-
burg (The Netherlands) from January 2007 until September
2008. After primary fracture care, a specialized nurse invited all
patients to the fracture and osteoporosis outpatient clinic of the
hospital for bone mineral density (BMD) measurement and lab-
oratory tests. Fractures were classified according to Center et al.
(9) into hip fractures, major fractures (vertebra, pelvis, distal
femur, proximal tibia, multiple rib, and humerus), minor frac-
tures (all remaining osteoporotic fractures, except fingers and
toes), and finger and toe fractures. Patients with metastatic can-
cer tobone,high-impactmultitrauma,osteomyelitis, or failureof
a prosthesis were excluded (n 9). Patients who responded and
agreed received adetailedquestionnaire for evaluationof clinical
risk factors for fractures, medical history, medication, previous
fractures, and calcium intake and were planned for dual x-ray
absorptiometry (DXA) measurement and a blood test. A visit at
the outpatient clinic was scheduled after completion of these
tests. At this visit height and weight were assessed, the question-
naire was evaluated and when necessary additional questions
were asked, and physical examination was performed by a phy-
sician. If laboratory results were abnormal, additional investi-
gations were performed for detailed evaluation of newly diag-
nosed disorderswhen necessary.Depending on the BMDresults,
calcium intake and serum25-hydroxyvitaminD [25(OH)D] lev-
els, patients were treated with adequate calcium intake, vitamin
D supplements, and antiosteoporosis medication according to
the Dutch guidelines for treatment of osteoporosis (10).
Data collection
The following demographic and historical data were col-
lected from each subject 2–4 months after fracture: age, ethnic-
ity, age atmenopause, current dietary and supplemental calcium
intake, vitamin D supplementation, regular exercise, history of
cigarette smoking (ever smoked vs. never smoked), and alcohol
intake (3 U/d or more vs. less than 3 U/d); medical and pharma-
cological history including previous fractures, nephrolithiasis,
years of estrogen replacement use; the use of other antiresorptive
agents and diuretics; and family history (first and second degree
relatives) of osteoporosis or fractures. Height, weight, and body
mass index (kilograms per square meter) were recorded.
Dietary calcium intakewasascertained froma food frequency
questionnaire and completed by 524of the 626 subjects and then
reviewed by the physician during the outpatient clinic visit. The
questionnaire was constructed by compiling a list of foods with
the highest calcium content, primarily dairy products including
milk and cheese consumption, and asking the subjects to indicate
their daily and weekly consumptions of these food products.
Total calcium intake was calculated by adding the average daily
dietary calcium intake as evaluated by long-term intake dietary
records (11) to the dosage and frequency of daily calcium
supplements.
Bone densitometry
BMD in the left or right hip and the lumbar spine was deter-
mined using DXA with the Hologic QDR 4500 (Hologic, Bed-
ford, MA). Diagnosis of osteoporosis was based on the World
Health Organization criteria for BMD (12), as provided by the
manufacturer for women and men and which are based on the
NationalHealthandNutritionExaminationSurvey III database.
T-score calculations were done for womenwith a female and for
men with a male reference population, as provided by the
manufacturer. Patients were classified according to the lowest
value of T-score in total hip, femoral neck, or lumbar spine:
osteoporosis as a T-score of 2.5 or less, osteopenia as a
T-score between 2.5 and 1.0, and normal BMD as a T-
score of 1.0 or higher.
Laboratory tests and abnormalities
Basic laboratory tests included serum sodium, potassium, cal-
cium, inorganic phosphate, albumin, creatinine, free tetraiodothy-
ronine (fT4), TSH, serum aminotransferases (aspartate amino-
transferase and alanine aminotransferase), alkaline phosphatase,
intact plasma PTH (iPTH), 25(OH)D, and serum and urine pro-
tein electrophoresis for all patients. The estimated glomerular
filtration rate (eGFR) was calculated using the modification of
diet in renal disease study group (MDRD) equation. The stages
of chronic kidney disease (CKD) were defined according to the
guidelines for CKD of the National Kidney Foundation (13).
Primary hyperparathyroidism was diagnosed by hypercalcemia
in the presence of inappropriately normal or elevated levels of
iPTH (14, 15). Secondary hyperparathyroidism was defined as
elevated plasma iPTH in combination with 25(OH)D less than
50 nmol/liter or CKD stage 3 or greater, or both. Hyperthyroid-
ism was defined by TSH values less than 0.40 mU/liter with
elevated fT4 levels and subclinical hyperthyroidism by TSH val-
ues less than 0.40 mU/liter with normal fT4 levels. Hypogonad-
ism was defined as a clinical syndrome complex, which com-
prises both symptoms as well as biochemical testosterone
deficiency. Testosterone deficiency was defined by a total tes-
tosterone level less than 8 nmol/liter (16). When inappropriate,
additional evaluation followed. Serum and urine protein elec-
trophoresis was performed for detection of plasma cell disorders
(17, 18). The diagnosis of MGUS required a serum monoclonal
protein, less than 10%bonemarrow plasmacytosis, no evidence
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of other B-cell proliferative disorders, and no end organ damage
due to the plasma cell proliferative process (i.e. bone lesions,
hypercalcemia, renal insufficiency, anemia) (19).
Statistics
SPSS software (version 16.0; SPSS Inc., Chicago, IL)was used
for the statistical analyses. Descriptive statistics, 2, and
ANOVAwere used for comparing the responders with the non-
responders and the participating men and women on baseline
fracture locations and BMD.
To identify the possible predictors for SECOB, possible risk
factors were assessed using multivariable logistic regression
models. Possible risk factors included in the model were age,
weight, height, BMD (normal, osteopenia, osteoporosis at any
side), prior fracture after the age of 50 yr, location of current
fracture, previously known SECOB, use of a walking aid, diffi-
culties getting up from a chair, current smoking, and alcohol
intake of 3 U/d or more.
Because low calcium intake and vitamin D deficiency are
mentioned as the most common types of SECOB in several stud-
ies, even though they are not treated separately as such in guide-
lines, additional descriptive analyses are presented for patients
with new SECOB, with and without secondary hyperparathy-
roidism, and according to adietary calcium intake less than1200
mg/d and 25(OH)D levels less than 50 nmol/liter.
Results
In total, 893consecutivepatients (221menand672women)
with a clinical vertebral or nonvertebral fracture were asked
to participate in this study. Two hundred thirty-seven sub-
jects (70 men and 167 women) did not respond to the invi-
tation or did not agree or were not able to participate.
Twenty subjects with one or more vertebral fractures (five
men and 15 women) were excluded because no DXA mea-
surement was performed. Additionally, 10 patients (two
men and eight women) were excluded because laboratory
resultswere not available. Therefore, 626 subjects (144men
and 482 women) were available for this study. Characteris-
tics of these patients are shown in Table 1.
The distribution of the different types of fractures in the
patients who responded and were eligible for this study
and nonresponders are as following: the nonresponders
were significantly older (74.9  11.5 vs. 69.9  10.7 yr;
P0.0001), consistedofmoremen (men: 29.5 vs.23.0%;
P 0.047), and sustained significantly more hip fractures
(22.8 vs. 8.0%; P 0.0001) but significantly fewer other
major fractures (26.6 vs. 33.1%; P  0.034).
Of the fracture patients, 15.0% had normal BMD
(men: 16.7%andwomen: 14.5%), 45.7%hadosteopenia
(men: 55.6% and women: 42.7%), and 39.3% had os-
teoporosis (men: 27.8% and women: 42.7%). Compared
with patients who sustained minor and major fractures,
significantly more patients with a hip fracture had low
BMD (P  0.0001). Osteopenia was found in 49.1% of
patients with a minor fracture, in 39.1% of patients with
a major fracture, and in 42.0% of patients with a hip frac-
ture, andosteoporosiswas found in31.4%(minor fracture),
49.3% (major fracture), and 58.0% (hip fracture).
We found a total number of 207 known contributors to
SECOB in 144 patients (23.0%); 58 patients had two or
more known factors (Table 2). In 166 of the 626 patients
(26.5%), 200 previously undetected disorders with a po-
tential influence on bone or mineral metabolism were
identified, 27of themhad two, twohad three, andone had
four new SECOBs. The frequency of various newly de-
tected disorders is shown in Table 3. We found monoclo-
nal proteinemia (14of626), renal insufficiencygrade III or
more (54 of 626), primary (17 of 626) and secondary (64
of 626) hyperparathyroidism, hyperthyroidism (39 of
626), and hypogonadism inmen (12 of 144). Patientswith
vitamin D deficiency were not included in the SECOB
counts unless they had secondary hyperparathyroidism.
We also found eight patients with unexplained elevated
iPTH levels, these were not included into the newly diag-
nosed SECOB group.
Additionally, in 43 patients alkaline phosphatase was
elevated (140 IU/liter); in 27 patients it normalized after
3–4 months and therefore is most likely related to the
recent fracture. In nine patients biliary problems were de-
tected; in six patients with only slightly elevated levels
(between 140 and 160 IU/liter), we have no follow-up
data; and one patient had a blunt abdominal trauma with
ascites. Erythrocyte sedimentation rate (ESR) was ele-
vated in 67 patients; 20 of these patients had a confirmed
pulmonary or urinary tract infection with normalization
of ESR, four patients had active rheumatoid arthritis or
polymyalgia rheumatica, three patients had a chronic el-
evated ESR of unknown origin, one patient was later di-
agnosed with liver cirrhosis, and one patient had a pan-
creatic carcinoma at follow-up.
Newlydiagnosedcontributors toSECOBwere foundat
any age, in both sexes, after any fracture (except in men
with finger and toe fractures) and at any level of BMD.We
TABLE 1. Characteristics of patients presenting with a
clinical vertebral or nonvertebral fracture
Variables
Men
(n  144)
Women
(n  482)
Age (yr) 66.0  10.2 71.0  10.6
Height (cm) 175.4  7.5 162.5  6.7
Weight (kg) 78.7  13.2 68.5  12.9
Body mass index 25.6  3.8 26.0  4.6
T-score lumbar spine 1.3  1.5 1.8  1.3
T-score femoral neck 1.5  1.1 1.7  1.1
T-score total hip 1.0  1.1 1.3  1.2
Dietary calcium intake (mg/d) 763  301 860  290
25(OH)D (nmol/liter) 50.7  26.2 40.1  22.8
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found one or more new contributors in 44 patients who
already had a known contributor at the moment of the
fracture (30.6%). The percentage of patients with a
newly detected contributor to SECOB was inversely re-
lated to BMD. In patientswith a normal BMD,we found
a newly diagnosed factor in 16.7% of the male and in
only 7.1% of the female patients. With osteopenia we
found a new factor in 23.8 and 27.7% of men and
women, respectively. In the patients with osteoporosis,
a new factorwas diagnosed in 42.5%ofmen and 31.1%
of women (Table 4).
The multivariable logistic regression analysis showed
that increasing age [odds ratio (OR) 1.04, confidence in-
terval (CI) 1.02–1.06)], being male (OR 1.78, CI 1.16–
2.73), having osteopenia (OR 2.67, CI 1.34–5.32), and
having osteoporosis (OR 2.98, CI 1.47–6.05; normal
BMD as reference) were significant risks. No interactions
were found, and therefore, all risk factors are independent
risk factors.
A serum 25(OH)D less than 50 nmol/liter was found in
400 patients (63.9%), 75.9% in 166 patientswith a newly
detected contributor to SECOB (50%with secondary hy-
perparathyroidism and 50% with normal PTH) and
59.6% in 460 patients without newly detected contribu-
tors to SECOB (with by definition a normal PTH). If pa-
tients with 25(OH)D less than 50 nmol/liter, regardless of
the presence of secondary hyperparathyroidism, would
also have been labeled as having SECOB, the number of
patients with a newly diagnosed contributor to SECOB
would have been 440 (70.3%). With a cutoff level of se-
rum 25(OH)D less than 75 nmol/liter, the number of pa-
tients with newly detected SECOB would even have been
563 (89.9%).
Based on the data of 524 patients who completed the
food questionnaire, only 9.4%had a dietary daily calcium
intake of 1200 mg/d or greater, whereas 58.2% had a
dietary daily calcium intake less than 1200 mg in combi-
nation with a 25(OH)D level less than 50 nmol/liter (see
Fig. 1). In combination with a vitamin D level less than 75
nmol/liter, this was even 80.3%.
TABLE 2. Prevalence of known contributors to SECOB at presentation with a clinical fracture
Known contributor
Number of patients
(percent of total)
Number of Women
(percent of all women)
Number of Men
(percent of all men)
History of glucocorticoid use 53 (8.5%) 42 (8.7%) 11 (7.6%)
Premature ovarian failure 25 (4.0%) 25 (5.2%) —
History of alcoholism 16 (2.6%) 4 (0.8%) 12 (8.3%)
History of hyperthyroidism 4 (0.6%) 4 (0.8%) 0
Current anticonvulsant use 6 (1.0%) 5 (1.0%) 1 (0.7%)
History of rheumatoid arthritis or systemic
lupus erythematosis
32 (5.2%) 25 (5.2%) 2 (1.4%)
History of COPD 65 (10.4%) 49 (10.2%) 16 (11.1%)
History of CKD 3 (0.5%) 3 (0.6%) 0
History of inflammatory bowel disease
or malabsorption
3 (0.5%) 2 (0.4%) 1 (0.7%)
Total (with one or more factors)a 144 (23.0%) 115 (23.9%) 29 (20.1%)
COPD, Chronic obstructive pulmonary disease; –, not applicable.
a We found a total number of 207 known contributors in 144 patients, and 58 patients had two or more known contributors.
TABLE 3. Newly diagnosed contributors to SECOB in
men and women with a clinical fracture
Disorders
Prevalence of newly diagnosed
contributors to SECOB
Men
(n  144)
Women
(n  482)
Total
(n  626)
n % n % n %
MGUS/myeloma 4/1 2.8/0.7 9/0 1.9/0 13/1 2.1/0.2
CKD
Stage 3 7 4.9 45 9.3 52 8.3
Stage 4 1 0.7 1 0.2 2 0.3
Hyperparathyroidism
(HPT)
1°a 1 0.7 16 3.3 17 2.7
2° due to vitamin
D deficiency
11 7.6 38 7.9 49 7.8
2° due to CKD 2 1.4 4 0.8 6 1.0
2° due to vitamin
D deficiency and
CKD
0 0 9 0.8 9 1.4
Hyperthyroidismb 8 5.6 31 6.4 39 6.2
Hypogonadism 12 8.3 12 1.9
Total number of
new
contributors
47 153 200
Patients with at least
one new
contributorc
40 27.8 126 26.1 166 26.5
a Of the 17 patients with primary hyperparathyroidism (2.7%), 12 (1.9%)
had elevated, and five (0.8%) inappropriately normal iPTH levels.
b Of the 39 patients with hyperthyroidism (6.2%), 30 (4.8%) were
diagnosed with overt and nine (1.4%) with subclinical hyperthyroidism.
c Because there were 31 subjects (six men and 25 women) with more
than one contributor to SECOB, the total number of men and women
with one or more contributors is lower than the sum of the individual
contributors (1°  primary HPT, 2°  secondary HPT).
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In Fig. 2, the percentages of patients with a new con-
tributor to SECOB, 25(OH)D level less than50nmol/liter,
and a daily dietary calcium intake less than 1200 mg are
presented. Newly diagnosed contributors to SECOB, se-
rum 25(OH)D less than 50 and 75 nmol/liter, and dietary
calcium less than 1200 mg/d were found in both sexes, at
any age, after any fracture (except SECOB in men with
finger and toe fractures) and at any level of BMD. The
percentage of patients with a new contributor to SECOB
was significantly different for age decades, skeletal status
(both P 0.001), and fracture type (P 0.05) but not for
sex.Thepercentageof patientswith25(OH)D less than50
nmol/literwas significantly different for age decades, skel-
etal status (both P 0.001), sex (P 0.01), and fracture
type (P  0.05). There was no significant difference for
calcium intake less than 1200 mg/d between age decades,
fracture type, sex, and skeletal status.
Discussion
In this study we investigated the prevalence of previously
undiagnosed contributors to SECOB in consecutive pa-
tients with clinical fractures. Our study indicates that un-
diagnosed contributors are present in 26.1% of women
and27.8%ofmenafter age50yrpresentingwith a clinical
fracture.When patients with already knownmediators or
diseases affecting bone and mineral metabolism are taken
into account (i.e. 23.0%), a total of 42.5%of patients had
one or more known or new contributors to SECOB. In
addition, a high percentage of patients had deficient di-
etary calcium intake in combination with vitamin D de-
ficiency, even when calculated according to the most con-
servative thresholds.
A remarkable finding was that newly diagnosed con-
tributors to SECOB, serum 25(OH)D less than 50 nmol/
liter, and calcium intake less than 1200 mg/d, were found
in both sexes, at all ages, after all fractures
(except SECOB inmenwith fractures of fin-
gers and toes), and at any level of BMD.The
clinical implication is that all patients at the
time of a clinical vertebral or nonvertebral
fracture should be evaluated for the pres-
ence of previously unknown SECOB con-
tributors and adequate calcium intake and
vitamin D status. From a semantic point of
view, we therefore extended the term “sec-
ondary osteoporosis” with the term “met-
abolic bone disease” into SECOB, including
vitamin D deficiency with secondary hyper-
parathyroidism. If, in addition, all patients
with serum 25(OH)D levels less than 50
nmol/liter regardless of PTH level were in-
cluded, 70.3% would have been diagnosed
with one or more newly diagnosed contrib-
utors to SECOB. If all patients with serum
25(OH)D level less than 75 nmol/liter were
included, 89.9%of patients would have been
labeled to have one or more contributors to
SECOB.
FIG. 1. Serum 25(OH)D levels (x-axis) and the daily calcium intake (y-axis) in 524
patients older than 50 yr at the time they present with a clinical vertebral or
nonvertebral fracture. Number and percentages of the patients are given for the four
quadrants.
TABLE 4. Prevalence of newly diagnosed contributors to SECOB in men and women with a fracture according to
skeletal status (normal BMD, osteopenia, and osteoporosis)
Newly diagnosed contributors to SECOB
Men Women
No (%) Yes (%) No (%) Yes (%)
Normal BMD 20 (83.3%) 4 (16.7%) 65 (92.9%) 5 (7.1%)
Osteopenia 61 (76.3%) 19 (23.8%) 149 (72.3%) 57 (27.7%)
Osteoporosis 23 (57.5%) 17 (42.5%) 142 (68.9%) 64 (31.1%)
Total 104 (72.2%) 40 (27.8%) 356 (73.9%) 126 (26.1%)
Patients with vitamin D deficiency were not included unless they had secondary hyperparathyroidism.
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Previous studies have reported the yield of laboratory
screening to detect underlying disorders in patients with
osteoporosis (5, 7, 20). Johnson et al. (20) identified pre-
viously unrecognized contributors to osteoporosis in 11%
of 180 patients with osteoporosis and bone densities that
were lower than expected for age, although a limited num-
berof laboratory investigationswasused.Deutschmann et
al. (7) reported a total of known and new risk factors for
osteoporosis in 63%ofwomen and 67%ofmen, the larg-
est groups of disorders being lactose malabsorption,
hypercalciuria, and renal tubular acidosis type 1. Tan-
nenbaum et al. (5) identified a prevalence of 32% of
previously unrecognized contributors to osteoporosis
in otherwise healthy postmenopausal women with os-
teoporosis. Although the prevalence of SECOB contrib-
utors is comparable with the results found in the present
study, the disorders identified differ between both
studies.
An important limitation of our study is that we did not
systematically evaluate 24-h urine analysis and malab-
sorption, especially celiac disease. Because low vitamin D
levels, secondary hyperparathyroidism, and/or low abso-
lute urinary calciumexcretionmaybe seen inpatientswith
celiac disease, this can be of important influence on the
results. In literature, the prevalence of celiac disease in
patients with osteoporosis was reported to be 1–3% (5,
21, 22). Additionally, Tannenbaum et al. (5) reported that
6.4% of women with osteoporosis had low 24-h urine
calcium (indicating calcium malabsorption) and 9.8%
had hypercalciuria. It is possible that the unknown ele-
vated iPTH levels in eight patients in our study could have
been explainedwhen routine 24-h urine analysis had been
performed. Given these limitations, we presume that the
percentage of patients with new SECOB contributorsmay
be even higher than the 26.5% found in our study.
The routine evaluation of ESR and alkaline phospha-
tase did not contribute to the finding of new contributors
to SECOB, and these parameters were predominantly re-
lated to postfracture infection and fracture healing, re-
spectively, but some other diseases were detected at fol-
low-up based on the abnormality of these parameters.
More recently several studies reported theprevalenceof
SECOB in fracture patients with osteoporosis (8), elderly
patientswith osteoporotic fractures admitted to a hospital
(23), and patients with hip fractures (24). Excluding vi-
tamin D deficiency, Dumitrescu et al. (8) reported newly
diagnosed SECOB contributors in approximately 10% of
fracture patients with osteoporosis. In a recent study by
Edwards et al. (24) in hip fracture patients, the number of
newly diagnosed SECOBcontributors is high and seems to
be comparable with the results in the patients with hip
fractures in our study, although the exact number of pa-
tients with one or more SECOB contributors, excluding
the patients with vitamin D deficiency, cannot be ex-
tracted from this paper.
We identifiedhyperthyroidismandprimaryhyperpara-
thyroidism in 6.2 and 2.7% of fracture patients, respec-
tively. Both disorders are associatedwith loss of BMDand
increased fracture risk, and after adequate treatment, frac-
ture risk declines (25, 26). In a recent review, it was ad-
vocated that patients with (subclinical) hyperthyroidism
should be additionally tested by a BMDmeasurement and
in case of reducedBMDshouldbe treatedwith antithyroid
drugs.Webelieve therefore that it is important todiagnose
overt but also subclinical hyperthyroidism inpatientswith
a recent clinical fracture (27). Osteopenia, osteoporosis,
and fracture prevalence rates are higher in hypogonadal
men of all ages, and bone density increases under testos-
terone substitution (16). Fracture data are not yet avail-
able, and thus, the long-term benefit of testosterone
requires further investigation. The prevalence of hypogo-
nadism found in men with fractures after age 50 yr in our
study (8.3%) emphasizes these guides.
The finding of MGUS is relatively frequent in patients
with osteoporosis or a fracture, (18, 24), and the risk of
fracture appears to be increased, even before progression
to myeloma (28). Screening for plasma cell disorders with
serum and urine protein electrophoresis is recommended
in patients with age-inappropriate bone loss, defined as
fragility fractures, osteopenia, or osteoporosis in patients
younger than65yr (17, 18).Although treatmentofMGUS
is not necessary, follow-up for early detection of progres-
FIG. 2. Percentages of patients with newly diagnosed contributors to
secondary osteoporosis and metabolic bone disease (black columns),
serum 25(OH)D level less than 50 nmol/liter (gray columns), and dietary
calcium intake less than 1200 mg/d (white columns) according to sex,
age, fracture location, and BMD. The percentage of patients with a
new contributor to SECOB was significantly different for age decades,
skeletal status (both P  0.001), and fracture type (P  0.05) but not
for sex. The percentage of patients with 25(OH)D less than 50 nmol/
liter was significantly different for age decades, skeletal status (both
P  0.001), sex (P  0.01), and fracture type (P  0.05). There was no
significant difference for calcium intake less than 1200 mg/d between
age decades, fracture type, sex, and skeletal status.
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sion to myeloma is warranted (18). Hence, evaluation for
plasma cell disorder in patients with clinical fracturesmay
be of relevance in identifying those at higher risk for future
fractures and also recognition of those who require addi-
tional therapy for more progressive myeloma disease.
Newly diagnosed CKD was found in 8.6% of the pa-
tients in our study, and 28% of them had concurrent sec-
ondary hyperparathyroidism (in 16% combined with vi-
taminDdeficiency). Twopatientswhose eGFRwasbelow
30 ml/min per 1.73 m2 (stage 4 CKD) were not eligible to
receive bisphosphonate therapy (35ml/min per 1.73m2
for zoledronate) basedon the current EuropeanMedicines
Agency and Food and Drug Administration product in-
formation. In recent studies in patients with fractures and
osteoporosis after the age of 50 yr, 6%of the patientswere
newly diagnosed with CKD (eGFR 45 ml/min per 1.73
m2) (8). In hip fracture patients, the percentage of patients
with CKD stage 3 and 4was 12 and 4%, respectively (24),
and in patients with low trauma fractures, the percentage
of patientswith stage3and4CKDwas reported tobe25.1
and 1.8%, respectively (29). Onset and severity of bone
disease and abnormalities of bonemineralmetabolism are
related to the level of GFR; below 60 ml/min per 1.73 m2,
there is a higher prevalence of abnormalities of bone me-
tabolism (13). Furthermore, fracture risk is increased in
patients with moderate to severe CKD, especially with a
eGFR less than 45 ml/min per 1.73 m2 (30). There is a
significant association between hip fracture andmoderate
to severe degrees ofCKD(31, 32). Thepathophysiological
alterations responsible for the renal osteodystrophy, such
as increased PTH, low vitamin D status, and disorders of
mineral metabolism, are evident at stage 3 of CKD. Based
on these findings, we propose routine evaluation of eGFR
in patients with a recent clinical vertebral or nonvertebral
fracture.
Conclusion
Based on the result of our study,we propose to perform
a detailed dietary questionnaire for evaluation of calcium
intake in combination with a panel of laboratory tests
comprising serum calcium, albumin, TSH, creatinine
(with calculation of eGFR), 25(OH)D, and serum and
urine protein electrophoresis in all patients presenting
with a fracture after age 50 yr and, in men, also serum
testosterone and, additionally, fT4 in patients with ab-
normal TSH and PTH in patients with abnormal serum
calcium. Laboratory testing is not contributory in men
with fractures of fingers and toes, except for serum
25(OH)D. We did not systematically perform 24-h urine
analysis and malabsorption tests, especially for celiac dis-
ease, but based on the results of studies in patients with
osteoporosis, these tests should also be considered in pa-
tients with a recent fracture. These analyses enable iden-
tification of previously unknown disorders related to sec-
ondary osteoporosis and metabolic bone disease that
should be corrected before osteoporosis medication is
started or need further follow-up and also warrant ade-
quate individually titrated calcium and vitamin D supple-
mentation in addition to antiosteoporosis medication in
patients with a recent fracture.
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